Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects

Next Previous
X
Search
Trial Profile

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contezolid (Primary)
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Feb 2017 Results from Part 1, 2 and 3, this and other two trials (see profile 239499 and 239500) published in the Antimicrobial Agents and Chemotherapy
    • 25 Feb 2015 Results published in a MicuRx Pharmaceuticals media release.
    • 25 Feb 2015 Status changed from not yet recruiting to completed, as reported in a MicuRx Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top